AXON - Axovant Sciences Ltd.

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
1.2200
-0.0700 (-5.43%)
At close: 4:00PM EST
Stock chart is not supported by your current browser
Previous Close1.2900
Open1.3000
Bid0.00 x 1000
Ask0.00 x 4000
Day's Range1.2000 - 1.3100
52 Week Range0.0580 - 6.5900
Volume2,783,720
Avg. Volume1,255,231
Market Cap189.751M
Beta (3Y Monthly)1.71
PE Ratio (TTM)N/A
EPS (TTM)-1.25
Earnings DateNov 6, 2017 - Nov 10, 2017
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est4.40
Trade prices are not sourced from all markets
  • GlobeNewswire4 days ago

    Axovant Announces Formation of Arvelle Therapeutics and Strategic Transition of Legacy Small Molecule Team Into Newly Formed Company

    Axovant Sciences (NASDAQ:AXGT), a clinical-stage company developing innovative gene therapies, today announces the formation of Arvelle Therapeutics and the strategic transition of its legacy small molecule team into the newly-formed company. Arvelle has licensed European rights to cenobamate, a novel investigational anti-epileptic drug for the potential treatment of focal (partial-onset) seizures, from SK Biopharmaceuticals.

  • Options Traders Expect Huge Moves in Axovant (AXON) Stock
    Zacks5 days ago

    Options Traders Expect Huge Moves in Axovant (AXON) Stock

    Investors need to pay close attention to Axovant (AXON) stock based on the movements in the options market lately.

  • Markit10 days ago

    See what the IHS Markit Score report has to say about Axovant Sciences Ltd.

    Axovant Sciences Ltd NASDAQ/NGS:AXONView full report here! Summary * ETFs holding this stock have seen outflows over the last one-month * Bearish sentiment is low * Economic output for the sector is expanding but at a slower rate Bearish sentimentShort interest | PositiveShort interest is low for AXON with fewer than 5% of shares on loan. The last change in the short interest score occurred more than 1 month ago and implies that there has been little change in sentiment among investors who seek to profit from falling equity prices. Money flowETF/Index ownership | NegativeETF activity is negative. Over the last one-month, outflows of investor capital in ETFs holding AXON totaled $2.84 billion. Additionally, the rate of outflows appears to be accelerating. Economic sentimentPMI by IHS Markit | NegativeAccording to the latest IHS Markit Purchasing Managers' Index (PMI) data, output in the Healthcare sector is rising. The rate of growth is weak relative to the trend shown over the past year, however, and is easing. Credit worthinessCredit default swapCDS data is not available for this security.Please send all inquiries related to the report to score@ihsmarkit.com.Charts and report PDFs will only be available for 30 days after publishing.This document has been produced for information purposes only and is not to be relied upon or as construed as investment advice. To the fullest extent permitted by law, IHS Markit disclaims any responsibility or liability, whether in contract, tort (including, without limitation, negligence), equity or otherwise, for any loss or damage arising from any reliance on or the use of this material in any way. Please view the full legal disclaimer and methodology information on pages 2-3 of the full report.

  • Associated Press11 days ago

    Axovant: Fiscal 3Q Earnings Snapshot

    On a per-share basis, the London-based company said it had a loss of 27 cents. The results met Wall Street expectations. The average estimate of five analysts surveyed by Zacks Investment Research was ...

  • GlobeNewswire11 days ago

    Axovant Announces Third Fiscal Quarter 2018 Financial Results and Corporate Updates

    Expanded pipeline with two investigational gene therapy programs licensed from the University of Massachusetts Medical School for the treatment of GM1 gangliosidosis, Tay-Sachs.

  • Athersys' (ATHX) MultiStem Cell Therapy Succeeds in Study
    Zacks25 days ago

    Athersys' (ATHX) MultiStem Cell Therapy Succeeds in Study

    Athersys (ATHX) gains on encouraging results from its exploratory study on the intravenous administration of MultiStem cell therapy to treat patients suffering from ARDS.

  • Amicus (FOLD) Boasts Strong Pipeline Amid Stiff Competition
    Zacks25 days ago

    Amicus (FOLD) Boasts Strong Pipeline Amid Stiff Competition

    Amicus (FOLD) is well placed after the United States approved its only marketed drug, Galafold, and the company added 14 new gene therapy programs to its pipeline for rare metabolic diseases.

  • Ultragenyx's Fatty Acid Disorder Candidate Succeeds in Study
    Zacks26 days ago

    Ultragenyx's Fatty Acid Disorder Candidate Succeeds in Study

    Ultragenyx releases encouraging top-line data from the phase III study on UX007 in patients with LC-FAOD.

  • ACCESSWIRE27 days ago

    Health Stocks Benefitting the Most from Rally

    HENDERSON, NV / ACCESSWIRE / January 22, 2019 / The stock market reached a level toward the end of last year where investors and analysts feared a recession. Some of this fear was over a U.S. China trade ...

  • ACCESSWIRElast month

    Market Rally Extends to Biotech

    HENDERSON, NV / ACCESSWIRE / January 9, 2019 / Markets are rallying in first full market week of 2019 and the biotech sector is responding as many oversold small caps are starting to rebound. We've found ...

  • Radius Exceeds 2018 Financial Guidance, Provides Updates
    Zackslast month

    Radius Exceeds 2018 Financial Guidance, Provides Updates

    Radius (RDUS) exceeds its 2018 financial guidance, with full-year U.S. net sales of its lead drug Tymlos surpassing the upper range of $95-$98 million.

  • Alnylam (ALNY) Reports Preliminary Onpattro Revenues for Q4
    Zackslast month

    Alnylam (ALNY) Reports Preliminary Onpattro Revenues for Q4

    Alnylam (ALNY) reports preliminary revenues for Onpattro for the fourth quarter of 2018, and also provides other updates.

  • GlobeNewswire2 months ago

    Axovant Announces Presentation at J.P. Morgan Healthcare Conference and Anticipated 2019 Clinical Development Milestones

    Axovant Sciences (AXON), a clinical-stage company developing innovative gene therapies, today announced that the company will be presenting at the 37th Annual J.P. Morgan Healthcare Conference. Pavan Cheruvu, M.D., chief executive officer, will present at 8:00 a.m. PST on Thursday, January 10th, 2019.

  • PR Newswire2 months ago

    Roivant Sciences to Present at the 37th Annual J.P. Morgan Healthcare Conference

    - In addition to Roivant, four Vants will be presenting at JPM this year NEW YORK and BASEL, Switzerland , Jan. 2, 2019 /PRNewswire/ -- Roivant Sciences today announced that Vivek Ramaswamy , Founder and ...

  • GlobeNewswire2 months ago

    Detailed Research: Economic Perspectives on Canopy Growth, ArQule, MoneyGram International, Teradata, Clovis Oncology, and Axovant Sciences — What Drives Growth in Today's Competitive Landscape

    NEW YORK, Dec. 26, 2018 -- In new independent research reports released early this morning, Market Source Research released its latest key findings for all current investors,.

  • Andreas Halvorsen Takes Large Stake in Axovant Sciences
    GuruFocus.com2 months ago

    Andreas Halvorsen Takes Large Stake in Axovant Sciences

    Guru sees value in biotech company

  • Could The Axovant Sciences Ltd. (NASDAQ:AXON) Ownership Structure Tell Us Something Useful?
    Simply Wall St.2 months ago

    Could The Axovant Sciences Ltd. (NASDAQ:AXON) Ownership Structure Tell Us Something Useful?

    The big shareholder groups in Axovant Sciences Ltd. (NASDAQ:AXON) have power over the company. Generally speaking, as a company grows, institutions will increase their ownership. Conversely, insiders often decrease their Read More...

  • PR Newswire2 months ago

    Roivant Sciences and Daiichi Sankyo Enter into Broad Pipeline Partnership

    NEW YORK and BASEL, Switzerland, Dec. 19, 2018 /PRNewswire/ -- Roivant Sciences today announced that it has entered into a collaboration with Daiichi Sankyo Company, Limited (hereafter, Daiichi Sankyo) to facilitate the out-licensing of investigational medicines. Under the terms of the agreement, Roivant will have the option to obtain exclusive licenses for certain development programs from Daiichi Sankyo on prespecified terms contingent on phase of development. Daiichi Sankyo has a wide range of compounds in development.

  • Benzinga2 months ago

    Upcoming Catalysts Make Axovant Attractive, Jefferies Says In Upgrade

    Axovant Sciences Ltd (NASDAQ: AXON ) plummeted 25 percent last week, providing an attractive entry point, as the company is in-licensing two promising orphan gene therapy programs that could have data ...

  • GlobeNewswire2 months ago

    Axovant Sciences Announces Pricing of $30 Million Public Offering of Common Shares

    Axovant Sciences (AXON) ("Axovant") today announced the pricing of its underwritten public offering of 30,000,000 of its common shares at a price to the public of $1.00 per share. Gross proceeds to Axovant from the offering are expected to be approximately $30,000,000 before deducting underwriting discounts and commissions and estimated offering expenses. All of the common shares are being offered by Axovant. In connection with this offering, Axovant has granted the underwriters a 30-day option to purchase up to an additional 4,500,000 of its common shares on the same terms and conditions.

  • ACCESSWIRE2 months ago

    Today's Research Reports on Trending Tickers: Axovant Sciences and Gilead Sciences

    NEW YORK, NY / ACCESSWIRE / December 14, 2018 / U.S. markets finished modestly higher on Thursday as investors continue to worry about trade tensions between the U.S. and China. The Dow Jones Industrial ...

  • GlobeNewswire2 months ago

    Axovant Sciences Announces Public Offering of Common Shares

    Axovant Sciences (AXON) ("Axovant") today announced that it has commenced an underwritten public offering of its common shares. All of the common shares are being offered by Axovant. In connection with this offering, Axovant expects to grant the underwriters a 30-day option to purchase additional common shares in the offering on the same terms and conditions.